Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer

Exclusion Criteria

• •Human epidermal growth factor receptor 2 (HER2)-positive or indeterminate G/GEJ cancer;
• •Pregnant or lactating women;
• •Positive pregnancy test for women in childbearing age. Menopausal women without menstruation for at least 12 months can be regarded as women with no possibility of getting pregnant;
• •Refusal of birth control during the study;
• •Prior chemotherapy, radiotherapy or immunotherapy;
• •History of other malignant diseases in the last 5 years (except for cervical carcinoma in situ);
• •History of uncontrolled central nervous system diseases, which could influence the compliance;
• •History of severe liver diseases (Child-Pugh class C), renal diseases (endogenous creatinine clearance rate (Ccr) ≤ 50 ml/min or SCr \> 1.5 ULN) or respiratory diseases; Uncontrolled diabetes and hypertension; Clinically severe heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure, uncontrolled arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 6 months;
• •History of dysphagia, complete or partial gastrointestinal obstruction, active gastrointestinal bleeding and gastrointestinal perforation;
• •On steroid treatment after organ transplant;
• •With uncontrolled severe infections;
• •Known dihydropyrimidine dehydrogenase deficiency (DPD);
• •Anaphylaxis to any research drug ingredient;
• •Known peripheral neuropathy (\> NCI-CTC AE 1). Patients with only disappearance of deep tendon reflex need not to be excluded.